Amgen: Riding The MariTide Of Monthly Weight Loss
MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...
Amgen starts two critical late-stage trials for weight loss drug MariTide
MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...
Fierce Biotech12d
Amgen enters Maritime, launching 2 late-stage obesity trials for MariTide
Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly ...
BioSpace1d
GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space
As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...
STAT11d
Amgen starts late-stage studies of MariTide
Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...
Amgen (NASDAQ:AMGN) Enters Late-Stage Testing on Weight Loss Drug
We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...
BioPharma Dive11d
Amgen readies pivotal MariTide trials; Novo offers discounted Wegovy
Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, the FDA cleared for ...
NBC 10 Philadelphia12d
Amgen starts two critical late-stage trials for weight loss drug MariTide
Amgen on Wednesday said it has started two critical late-stage trials for its experimental weight loss injection MariTide, another step in its bid to enter the booming obesity drug market. " ...